Aestas Pharma Inc. is dedicated to the development of novel diagnostic imaging and therapeutic agents to enable the EARLY detection and REVERSAL of severely debilitating Alzheimer’s diseases (AD) and Parkinson’s disease (PD). In marked contrast to competitor's approaches, including development stage diagnostic agents and drugs, Aestas is focused on targeting the very earliest stages of AD and PD, when clinical signs are not yet pronounced.